Literature DB >> 11443067

Factor Xa is a fibroblast mitogen via binding to effector-cell protease receptor-1 and autocrine release of PDGF.

O P Blanc-Brude1, R C Chambers, P Leoni, W A Dik, G J Laurent.   

Abstract

The coagulation cascade protease thrombin is a fibroblast mitogen, but the proliferative potential of other coagulation proteases is not known. In this study we show that factor Xa stimulated human fetal lung fibroblast DNA synthesis in a concentration-dependent manner from 1 nM onward with a fourfold increase at 200 nM. The mitogenic effect of factor Xa was confirmed using a colorimetric proliferation assay and direct cell counting. Factor Xa and thrombin had equivalent potencies, and their stimulatory effects followed a similar time course. Comparable results were also obtained with primary human adult fibroblasts derived from lung, kidney, heart, skin, and liver. Factor VIIa also stimulated fibroblast proliferation, but only at concentrations >10 nM, whereas factor IXa had no effect. To begin to address the mechanism by which factor Xa is acting, we show that human fibroblasts express effector-cell protease receptor-1 and that blocking antibodies to this receptor and the catalytic site of factor Xa inhibited its mitogenic effect. Furthermore, factor Xa upregulated platelet-derived growth factor-A (PDGF-A) mRNA expression, whereas PDGF-B could not be detected, and a blocking antibody to PDGF inhibited the mitogenic effect of factor Xa. We conclude that factor Xa acts as a fibroblast mitogen via binding to effector-cell protease receptor-1 and the autocrine release of PDGF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443067     DOI: 10.1152/ajpcell.2001.281.2.C681

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  8 in total

Review 1.  Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways.

Authors:  Henri H Versteeg; C Arnold Spek; Maikel P Peppelenbosch; Dick J Richel
Journal:  Mol Med       Date:  2004 Jan-Jun       Impact factor: 6.354

Review 2.  The Therapeutic Potential of Anticoagulation in Organ Fibrosis.

Authors:  Hanna Oh; Hye Eun Park; Min Su Song; HaYoung Kim; Jea-Hyun Baek
Journal:  Front Med (Lausanne)       Date:  2022-05-16

3.  Significance of effector protease receptor-1 expression and its relationship with proliferation and apoptotic index in patients with primary advanced gastric adenocarcinoma.

Authors:  Xue-Quan Yao; Fu-Kun Liu; Jie-Shou Li; Xiao-Ping Qi; Bo Wu; Hong-Lin Yin; Heng-Hui Ma; Qun-Li Shi; Xiao-Jun Zhou
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

Review 4.  Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?

Authors:  R C Chambers
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

5.  Regulatory mechanism of matrix metalloprotease-2 enzymatic activity by factor Xa and thrombin.

Authors:  Bon-Hun Koo; Michael Y Park; Ok-Hee Jeon; Doo-Sik Kim
Journal:  J Biol Chem       Date:  2009-07-06       Impact factor: 5.157

6.  Absence of proteinase-activated receptor-1 signaling in mice confers protection from fMLP-induced goblet cell metaplasia.

Authors:  Luigi Atzori; Monica Lucattelli; Chris J Scotton; Geoffrey J Laurent; Barbara Bartalesi; Giovanna De Cunto; Benedetta Lunghi; Rachel C Chambers; Giuseppe Lungarella
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-23       Impact factor: 6.914

7.  Molecular and cellular mechanisms of pulmonary fibrosis.

Authors:  Nevins W Todd; Irina G Luzina; Sergei P Atamas
Journal:  Fibrogenesis Tissue Repair       Date:  2012-07-23

Review 8.  Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.

Authors:  Claire S Whyte; Gael B Morrow; Joanne L Mitchell; Pratima Chowdary; Nicola J Mutch
Journal:  J Thromb Haemost       Date:  2020-06-03       Impact factor: 16.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.